PAWI-2

synergizes enzalutamide in in vitro inhibition of prostate cancer cell viability; structure in source

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

1.	Neoplasms (Cancer) 01/01/2021 - "In the present study, we showed PAWI-2 produced therapeutic synergism with certain types of anti-cancer drugs. " 12/01/2019 - "In vivo studies in a PC-3 xenograft model showed that PAWI-2 (20 mg/kg per day i.p., 21 days) inhibited tumor growth by 49% compared with vehicle-treated mice. " 01/01/2021 - "Key molecular regulators of PAWI-2 could be used to predict synergistic/antagonistic effects between PAWI-2 and other anti-cancer drugs. " 01/01/2020 - "The findings show PAWI-2 is a new approach to reverse tumor stemness that resensitizes CSC tumors to drug inhibition." 12/01/2019 - "Compared with vehicle-treated mice, PC-3 xenograft studies also showed that PAWI-2 (20 mg/kg per day i.p., 21 days) and enzalutamide (5 mg/kg per day i.p., 21 days) inhibited tumor growth by 63%. "
2.	Pancreatic Neoplasms (Pancreatic Cancer) 01/01/2021 - "PAWI-2 is a potent inhibitor of drug-resistant PC cells that has been shown to selectively ameliorate human pancreatic cancer stem cells (i.e., hPCSCs, FGβ3 cells). " 01/01/2020 - "PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin β3-KRAS-dependent pancreatic cancer stem cells."